Abstract

Simple SummaryC-terminal tensin-like, or CTEN, is a cytoskeletal protein that is expressed highly in head and neck cancer (HNSCC). We studied CTEN function using gene knockdown and found that CTEN contributes to HNSCC progression in several ways, promoting tumour cell invasion and also cell survival. Notably, CTEN expression protects tumour cells from radiation-induced apoptosis and consistent with this, we found that CTEN expression predicts for survival in patients treated with radiotherapy (but not surgery), suggesting that CTEN may have utility as a predictive marker of radiotherapy resistance.Head and neck squamous cell carcinoma (HNSCC) is a heterogenous disease treated with surgery and/or (chemo) radiotherapy, but up to 50% of patients with late-stage disease develop locoregional recurrence. Determining the mechanisms underpinning treatment resistance could identify new therapeutic targets and aid treatment selection. C-terminal tensin-like (CTEN) is a member of the tensin family, upregulated in several cancers, although its expression and function in HNSCC are unknown. We found that CTEN is commonly upregulated in HNSCC, particularly HPV−ve tumours. In vitro CTEN was upregulated in HPV−ve (n = 5) and HPV+ve (n = 2) HNSCC cell lines. Stable shRNA knockdown of CTEN in vivo significantly reduced tumour growth (SCC-25), and functional analyses in vitro showed that CTEN promoted tumour cell invasion, colony formation and growth in 3D-culture (SCC-25, Detroit 562). RNA sequencing of SCC-25 cells following CTEN siRNA knockdown identified 349 differentially expressed genes (logFC > 1, p < 0.05). Gene ontology analysis highlighted terms relating to cell locomotion and apoptosis, consistent with in vitro findings. A membrane-based antibody array confirmed that CTEN regulated multiple apoptosis-associated proteins, including HSP60 and cleaved caspase-3. Notably, in a mixed cohort of HPV+ve and HPV−ve HNSCC patients (n = 259), we found a significant, independent negative association of CTEN with prognosis, limited to those patients treated with (chemo)radiotherapy, not surgery, irrespective of human papillomavirus (HPV) status. These data show that CTEN is commonly upregulated in HNSCC and exerts several functional effects. Its potential role in modulating apoptotic response to therapy suggests utility as a predictive biomarker or radio-sensitising target.

Highlights

  • With over 500,000 new diagnoses each year and a mortality over 50% [1], the disease burden of head and neck cancer squamous cell carcinoma (HNSCC) is significant

  • Ginos Head-Neck [35] datasets revealed that mRNA expression of C-terminal tensin-like (CTEN) was significantly higher in HNSCC tissue samples compared with normal tissue (fold change 1.691 (p = 0.014) and 1.894 (p < 0.0001), respectively; Figure 1a,b)

  • Genome Atlas (TCGA) directory (n = 520; [4]) showed increased CTEN mRNA expression in tumour tissue compared to normal controls (p < 0.0001, Figure 1c), with expression significantly higher in advanced primary disease compared with early stage disease, and in Human papillomavirus (HPV)-negative disease compared with virally-derived tumours (p < 0.0001; Figure 1e)

Read more

Summary

Introduction

With over 500,000 new diagnoses each year and a mortality over 50% [1], the disease burden of head and neck cancer squamous cell carcinoma (HNSCC) is significant. Prognosis continues to be highly dependent on locoregional tumour burden, and late presentation of disease accounts for over 60% of new diagnoses [3]. Human papillomavirus (HPV) status is the only molecular stratifier used routinely in current clinical practice [5] (mostly identified by using p16 expression as a surrogate marker) and is the single most significant non-anatomical prognostic marker [6]. Despite a higher incidence of positive lymph node involvement at presentation, which tended to skew staging information in the American Joint

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call